NRAS and cutaneous melanoma: Additional investigation into “triple wild-type” cutaneous melanomas and their reliance on Ras/MAPK signaling is an area for further study, and poor outcomes in NRAS mutant tumors highlight an urgent, unmet clinical need for therapeutic development.